Kodiak Turns Back On Tarcocimab After Two Pivotal Trial Flops In DME
Stock Down 46%
Executive Summary
The US firm’s lead antibody biopolymer conjugate asset failed to match Regeneron/Bayer’s Eylea in two Phase III diabetic macular edema studies, prompting discontinuation of the program and a reassessment of an earlier program based on the same platform technology.